Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (151-160 of 315) with videos related to

Pageof 32
Sort By:
Dermatology and Therapy|October 24, 2019
Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, Laurent Eckert, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
The Journal of Dermatological Treatment|June 1, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trialAndrew Blauvelt, Eric L Simpson, Kilian Eyerich, et al.
The Journal of Investigative Dermatology|April 23, 2019
Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Journal of the American Academy of Dermatology|September 30, 2024
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 studyAmy S Paller, Jonathan I Silverberg, Eric L Simpson, et al.
The Journal of Investigative Dermatology|December 21, 2018
Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 21, 2018
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional studyJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 10, 2018
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
American Journal of Clinical Dermatology|May 6, 2021
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported OutcomesJonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, et al.
Pageof 32

Showing results (151-160 of 315) with videos related to

Sort By:
Pageof 32
Dermatology and Therapy|October 24, 2019
Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic DermatitisEric L Simpson, Marjolein de Bruin-Weller, Laurent Eckert, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
The Journal of Dermatological Treatment|June 1, 2026
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trialAndrew Blauvelt, Eric L Simpson, Kilian Eyerich, et al.
The Journal of Investigative Dermatology|April 23, 2019
Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Journal of the American Academy of Dermatology|September 30, 2024
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 studyAmy S Paller, Jonathan I Silverberg, Eric L Simpson, et al.
The Journal of Investigative Dermatology|December 21, 2018
Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in AdultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 21, 2018
Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional studyJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 10, 2018
Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adultsJonathan I Silverberg, Joel M Gelfand, David J Margolis, et al.
American Journal of Clinical Dermatology|May 6, 2021
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported OutcomesJonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, et al.
Pageof 32